Combining Acute Diffusion-Weighted Imaging and Mean Transmit Time Lesion Volumes With National Institutes of Health Stroke Scale Score Improves the Prediction of Acute Stroke Outcome

Background and Purpose— The purpose of this study was to determine whether acute diffusion-weighted imaging (DWI) and mean transit time (MTT) lesion volumes and presenting National Institutes of Health Stroke Scale (NIHSS) can identify patients with acute ischemic stroke who will have a high probability of good and poor outcomes. Methods— Fifty-four patients with acute ischemic stroke who had MRI within 9 hours of symptom onset and 3-month follow-up with modified Rankin scale were evaluated. Acute DWI and MTT lesion volumes and baseline NIHSS scores were calculated. Clinical outcomes were considered good if the modified Rankin Scale was 0 to 2. Results— The 33 of 54 (61%) patients with good outcomes had significantly smaller DWI lesion volumes (P=0.0001), smaller MTT lesion volumes (P<0.0001), and lower NIHSS scores (P<0.0001) compared with those with poor outcomes. Receiver operating characteristic curves for DWI, MTT, and NIHSS relative to poor outcome had areas under the curve of 0.889, 0.854, and 0.930, respectively, which were not significantly different. DWI and MTT lesion volumes predicted outcome better than mismatch volume or percentage mismatch. All patients with a DWI volume >72 mL (13 of 54) and an NIHSS score >20 (6 of 54) had poor outcomes. All patients with an MTT volume of <47 mL (16 of 54) and an NIHSS score <8 (17 of 54) had good outcomes. Combining clinical and imaging thresholds improved prognostic yield (70%) over clinical (43%) or imaging (54%) thresholds alone (P=0.01). Conclusions— Combining quantitative DWI and MTT with NIHSS predicts good and poor outcomes with high probability and is superior to NIHSS alone.

[1]  Keith Muir,et al.  Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial , 2008, The Lancet Neurology.

[2]  P Sandercock,et al.  Magnetic resonance perfusion diffusion mismatch and thrombolysis in acute ischaemic stroke: a systematic review of the evidence to date , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[3]  S. Warach,et al.  The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A Phase II MRI-Based 9-Hour Window Acute Stroke Thrombolysis Trial With Intravenous Desmoteplase , 2005, Stroke.

[4]  G. Schlaug,et al.  Evaluation of the Clinical–Diffusion and Perfusion–Diffusion Mismatch Models in DEFUSE , 2007, Stroke.

[5]  P. Barber,et al.  Clinical–Diffusion Mismatch and Benefit From Thrombolysis 3 to 6 Hours After Acute Stroke , 2009, Stroke.

[6]  L. Caplan,et al.  Stroke Thrombolysis: Slow Progress , 2006, Circulation.

[7]  Wade S. Smith,et al.  Prognostic significance of angiographically confirmed large vessel intracranial occlusion in patients presenting with acute brain ischemia , 2006, Neurocritical care.

[8]  C. Weiller,et al.  Outcome and Symptomatic Bleeding Complications of Intravenous Thrombolysis Within 6 Hours in MRI-Selected Stroke Patients: Comparison of a German Multicenter Study With the Pooled Data of ATLANTIS, ECASS, and NINDS tPA Trials , 2006, Stroke.

[9]  S. Warach,et al.  Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion–diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study , 2009, The Lancet Neurology.

[10]  K. Pettigrew,et al.  Progression in acute stroke: value of the initial NIH stroke scale score on patient stratification in future trials. , 1999, Stroke.

[11]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[12]  Brian Silver,et al.  A three-item scale for the early prediction of stroke recovery , 2001, The Lancet.

[13]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[14]  M. Kaste,et al.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.

[15]  R. Gonzalez,et al.  MRI-Based Selection for Intra-Arterial Stroke Therapy: Value of Pretreatment Diffusion-Weighted Imaging Lesion Volume in Selecting Patients With Acute Stroke Who Will Benefit From Early Recanalization , 2009, Stroke.

[16]  B. Rosen,et al.  High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis , 1996, Magnetic resonance in medicine.

[17]  A. Villringer,et al.  Effect of Intravenous Thrombolysis on MRI Parameters and Functional Outcome in Acute Stroke <6 Hours , 2002, Stroke.

[18]  W. Hacke,et al.  Mismatch-Based Delayed Thrombolysis: A Meta-Analysis , 2010, Stroke.

[19]  P. Kaňovský,et al.  Impact of diffusion-weighted MRI-measured initial cerebral infarction volume on clinical outcome in acute stroke patients with middle cerebral artery occlusion treated by thrombolysis , 2006, Neuroradiology.

[20]  À. Rovira,et al.  Safety and Efficacy of Intravenous Tissue Plasminogen Activator Stroke Treatment in the 3- to 6-Hour Window Using Multimodal Transcranial Doppler/MRI Selection Protocol , 2005, Stroke.

[21]  Jeffrey L Saver,et al.  The Impact of Recanalization on Ischemic Stroke Outcome: A Meta-Analysis , 2007, Stroke.

[22]  M. Vangel,et al.  ABC/2 for rapid clinical estimate of infarct, perfusion, and mismatch volumes , 2009, Neurology.

[23]  Henry Ma,et al.  Penumbral selection of patients for trials of acute stroke therapy , 2009, The Lancet Neurology.

[24]  Scott Hamilton,et al.  Magnetic resonance imaging profiles predict clinical response to early reperfusion: The diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study , 2006, Annals of neurology.

[25]  H. Moriwaki,et al.  Baseline NIH Stroke Scale Score predicting outcome in anterior and posterior circulation strokes , 2008, Neurology.

[26]  Steven Warach,et al.  Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of Safety and Efficacy 3 to 9 Hours After Stroke Onset , 2006, Stroke.

[27]  Patricia Desmond,et al.  Clinical-Diffusion Mismatch Predicts the Putative Penumbra With High Specificity , 2005, Stroke.

[28]  T. Neumann-Haefelin,et al.  MRI-Based and CT-Based Thrombolytic Therapy in Acute Stroke Within and Beyond Established Time Windows: An Analysis of 1210 Patients , 2007, Stroke.